Climb Career Mountains But Return Safe
One of the biggest myths for career seekers is their belief that it is an easy linear slope. This is the reason many struggle with some career plateaus. Some are surprised with sudden career cliffs; others are scared of the stiff heights of career hills. Career building in today’s world of turbulence and opportunity is more like adventure sport. Exhilarating and scary, possibly at the same step. You need to be spirited and yet you must avoid missteps. That is how new age careers will need to be – a series of experiences, the ups and the downs, the moments of high and the moments of low. The one who will understand this, prepare for this and, most of all, goes ahead to do it will be the one who will script a successful career.
Anyone who dreams of a career must have the energy and the passion to nurture one. Just having an education qualification or some prior experience is not it. It is the hunger to excel, to take chances, to make every indifferent opportunity a trailblazing experience. It is about infinite optimism to win. It is the tenacity to persevere. You need to have the career adrenaline.
The journey is exacting. There are phases of stretch and stress – physical, mental and emotional. You get exposed to negative influences and infected with the virus of cynicism. To ensure you stay strong and healthy on this exciting adventure you need to supplement your diet with additional nutrition. Special skills, rotation to different experiences, coaching, feedback, stretch projects, peer feedback – these help add that extra strength to a fundamentally good mind and body. They keep you agile, alert and well-sinewed.
Many of us strain ourselves, even enjoying that style, to perform, stretch and deliver always. While this is the adrenaline pumping and is wonderful, it is equally important to slow down at times. Take a break. A sabbatical. It is a phase to pause and reflect. Ask some fundamental questions about our purpose of life and doing. Reinforce beliefs. Repudiate myths and illusions. This is a time of rest and recovery. It may seem to be a plateau but has ahuge value for us.
The climber’s club
Careers have their highs and lows. There are giant boulders intimidating us. There are the loose rocks that can also become precipitous. You need to tread carefully -sometimes trusting your own instinct, at other times, connected and supported by fellow rock climbers. There is the need to give and take. It is foolish to assume, we can scale all the peaks all alone. Choosing the right set of fellow climbers is key. Each brings a strength that helps us move forward, safely but surely. We need to select right and trust right. Enabled by individual capability and powered by the safety norms of the collective. The instinct to trust, collaborate and encourage each other makes for successful climbing. This could be the difference to reaching the peak or falling to depths.
Celebrate the exhilaration
The peak is not always the most exciting moment of the expedition. It is more a metaphor for closure. There are many moments along the way that may be more demanding, exciting and fulfilling. We must learn to celebrate these exciting moments as much. Otherwise, waiting to celebrate only at the peak will make the trek up tedious and, possibly, uninspiring.
The climb down and after
Once you are up on the point that you dreamt about, soak in your achievement. And then open your eyes and look down. You also have to get back from where you started. Success can leave you isolated and lonely. Perched high above, with no one to celebrate with, can ironically be depressive. The ability and willingness to carefully climb down from this high is not one that every peak conqueror has. This is equally treacherous and threatening. Sometimes going up may seem easier than going down. This is where our true character and prowess may be tested.
This article originally appeared in Economic Times
Read it now
We wish you a very happy 72nd Indian Independence Day!
Seven decades after our historic tryst with destiny, on 15 August 2018, India will celebrate 72 years of independence, democracy and sovereignty. Presenting some interesting snippets from the archives on this occasion.
“India was officially proclaimed independent on 15th August 1947 with much celebrations in Delhi and other towns. Cipla celebrated the first Independence Day by a flag hoisting ceremony where all workers and staff of Cipla were present.”
– Dr. Khwaja Abdul Hamied,
‘A Life To Remember – An Autobiography’ (1972)
This is how India’s first Independence Day was celebrated by Cipla. The tricoloured Indian national flag was proudly unfurled and hoisted and the venue was Cipla’s very first manufacturing site and headquarters in Mumbai Central.
Cipla’s celebration of Indian independence did not end there. As a nationalist and freedom fighter, Dr. K.A. Hamied ensured that Cipla as an employer played its part in making the occasion unforgettable for Ciplaites by announcing a generous Independence Bonus!
The late Dr. A.R. Kidwai was a multi-faceted personality – public servant, scholar, statesman extraordinaire of post-independence India. Dr. Kidwai was a Cipla chemist from 1941 to 1945 and was witness to early scientific projects of Cipla as well as the involvement of then Ciplaites in the independence movement. Here’s a snippet of his reflections from the Oral History collection of the archives.
This advertisement placed by Cipla in the 1948 edition of the journal, Marg is a strong reminder of how Cipla was a trail-blazer in pharma R&D, quality and manufacturing in India, and saw itself as second to none. Spend a minute or two to read it with its context in mind – a time of euphoria, great promise, unrealised potential. A time when the state of India would finally attain equality in status with others on the world stage. Cipla’s strides were a microcosm of India’s in so many ways.
On that note, we wish you a very happy 72nd Indian Independence Day!
Cipla Receives Final Approval for Generic Reyataz® (Atazanavir Caps 100mg, 150mg, 200mg, 300mg)
Cipla Limited (“Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Atazanavir Caps 100mg, 150mg, 200mg, 300mg from the United States Food
and Drug Administration (US FDA).
Cipla’s Atazanavir Caps 100mg, 150mg, 200mg, 300mg is AB-rated generic therapeutic equivalent version of Bristol-Myers Squibb Pharma Company’s, Reyataz®. It is a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients with minimum age of 6 years and older weighing at least 15 kg.
According to IQVIA (IMS Health), Reyataz® and its generic equivalents had US sales of approximately $324M for the 12-month period ending April 2018.
Cipla partners with MSN Laboratories for marketing and distribution of generic Xeloda® (Capecitabine Tabs 150mg and 500mg)
Cipla USA, Inc., (“Cipla”) a subsidiary of Cipla Limited, today announced that it has secured rights from MSN Laboratories Private Limited to market & distribute Capecitabine 150mg and 500mg tablets in the United States of America. The product is available immediately.
The Capecitabine 150mg and 500mg tablet is an AB-rated generic therapeutic equivalent version of Genentech’s Xeloda®. Capecitabine tablets are indicated as a single agent for adjuvant treatment in patients with Dukes C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred, and also indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.
As per IQVIA (IMS Health), Xeloda® and its generic equivalents had sales of approximately $178M for the 12-month period ending June 2018 in the United States.
About MSN Group
Founded in 2003 with a mission to make health care affordable, the MSN Group based out of Hyderabad is one of the fastest growing research-based pharmaceutical company in India. MSN has 10 API (including Oncology) and
five finished dosage facilities out of which three in Hyderabad, one both in USA & Myanmar. MSN Labs has an integrated R&D Center for both API and product formulation under one roof. The company’s core strategy will be to focus on high barrier of entry & first to market paragraph 4 products. MSN customer base exceeds 250 customers with a global presence in 65 countries throughout US, Europe, Latin America, Middle-East, Asia Pacific, Africa and CIS markets. With more than 350 National & International patents filed, MSN’s product basket offers 300 APIs & 200 Formulations covering 35 major therapies.
Cipla Receives USFDA Approval for Generic Voltaren® Gel (Diclofenac Sodium Topical Gel, 1%)
Cipla Limited (“Cipla”) announced that it has received final approval on August 3, 2018, for its Abbreviated New Drug Application (ANDA) for Diclofenac Sodium Topical Gel, 1% from the United States Food and Drug Administration (US FDA).
Cipla’s Diclofenac Sodium Topical Gel, 1% is AB-rated generic therapeutic equivalent to the reference listed drug (RLD), Voltaren® Gel, 1% of GlaxoSmithKline Consumer Health®. It is a non-steroidal anti-inflammatory drug
indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands.
According to IQVIA (IMS Health), Voltaren® Gel and its generic equivalents had US sales of approximately $353M for the 12-month period ending June 2018. The product will be available for shipping in the US in the upcoming week.